^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    KRAS G12V inhibitor

    Related drugs:
    1m
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Suspended, Fred Hutchinson Cancer Center | Active, not recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    3ms
    Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Anocca AB
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    4ms
    AFNT211-22-101: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Affini-T Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    AFNT-211
    6ms
    A first-in-class EGFR-directed KRAS G12V selective inhibitor. (PubMed, Cancer Cell)
    Using a targeted RNAi delivery platform, we achieve effective tumor silencing of KRASG12V and significant anti-tumor activity across several cancer models. Our findings represent a technological advance in oncogene targeting using RNAi and provide new biologic insights in KRAS targeting with potential implications for safety and efficacy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    6ms
    A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation (clinicaltrials.gov)
    P1, N=9, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    7ms
    NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, Peking University
    New P1 trial
    7ms
    Identification and characterization of oncogenic KRAS G12V inhibitory peptides by phage display, molecular docking and molecular dynamic simulation. (PubMed, Comput Biol Med)
    Both peptides demonstrated significant inhibition of KRAS G12V-carrying cancer cell lines (NCI-H2444 and SW620), reducing cell viability by 70-75 % at 400 μM after 48 h while showing minimal effects (20-30 % reduction) on wild-type KRAS-carrying Caco-2 cells, which is equal to DMSO diluent control. These findings provide new insights into peptide-based targeting of KRAS G12V and demonstrate the potential of using subtractive phage display for developing selective inhibitors against oncogenic mutations.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    8ms
    A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Sun Yat-sen University
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    10ms
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 5
    Enrollment closed • Enrollment change • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    11ms
    QTX3544-201: QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=237, Recruiting, Quanta Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Erbitux (cetuximab)
    1year
    QTX3544 in Patients with Advanced Solid Tumors with KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=237, Not yet recruiting, Quanta Therapeutics
    New P1 trial • Metastases
    |
    Erbitux (cetuximab)
    over1year
    NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=9, Recruiting, Tao Zhang
    New P1 trial • Metastases